Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results

MT Newswires Live

06/05

Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.

The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in "Good On" time, and reductions in "Off" time, and improved motor symptom control.

"Good On" time refers to the amount of time without dyskinesia plus "on" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2641148300"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641148300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641148300?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641148300","market":"sg","top_or_hot":-1,"title":"Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results","media":"MT Newswires Live","content":"<html><body><p> Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.</p><p>The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.</p><p>\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-05 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.</p><p>The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.</p><p>\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641148300","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641148300","pubTimestamp":1780662628,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amneal Pharmaceuticals  said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Amneal Pharmaceuticals报告Crexont在4期中期结果中比Rytary提供了临床益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}